期刊
TRENDS IN MOLECULAR MEDICINE
卷 19, 期 5, 页码 309-319出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2013.03.004
关键词
multiple sclerosis; IFN beta; glatiramer acetate; TNF receptor 1; dimethyl fumarate monoclonal antibodies
资金
- Biogen Idec
- Teva
- Biogen Idec Germany
- Sanofi Aventis
- Novartis
- Bayer Healthcare
- Merck Serono
- Bayer
- Behring CSL
- Medical Research Council [G1000800i] Funding Source: researchfish
In recent years, multiple sclerosis (MS) research has progressed on several fronts, prompting numerous clinical trials, primarily for immunotherapeutics. Although several new therapies have been disappointing and some were revealed to have devastating side effects, others have shown benefits and all have generated valuable knowledge about the progression of MS, the key contributors to pathogenesis, and on natural surveillance mechanisms for brain infections. This makes now a useful time to take stock of recent advances in developing MS treatments and consider new approaches for adding information where the gaps are greatest - mainly in understanding the degenerative processes responsible for most of the long-term disability. Here, we summarize currently accepted therapeutic principles and the drugs in late stages of development, as well as spotlighting potential novel openings for future research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据